Schleifer, MD, President & CEO
Retatrutide syringe recommendations Retatrutide is a triple GLP-1/GIP/glucagon receptor agonist in research use
Common side effects include nausea, diarrhea, constipation, and vomiting
GLP-1s Are Lowering the Percentage of Americans With Obesity According to the same poll, the percentage of adults with obesity has also dropped to 37 percent, down from a record high of 39.9 percent in 2022
It appears safe to continue these medications before a procedure requiring anaesthesia or sedation, with minor precautions like abstaining from solid food for a day to minimize any potential risk of aspiration. Recent reports and studies suggest that taking GLP-1 medications is associated with slower digestion with a larger amount of food remaining in the stomach
Skin laxity is another concern with weight loss exceeding 15-20% of body weight